Blog
RSS FeedPosted by Michael Wonder on 19 May 2022
Budget 2022: PHARMAC boost leaves patients cold: 'it won't be enough'
19 May 2022 - PHARMAC has had its biggest ever funding boost, but some New Zealanders fear it still won’t ...
Posted by Michael Wonder on 19 May 2022
Medicines Australia puts spotlight on reform priority for the next Government
20 May 2022 - Medicines Australia has set the scene for major health reform by the next Government by alerting ...
Posted by Michael Wonder on 19 May 2022
Plea to make new depression 'spray' affordable
19 May 2022 - Mental health experts say a nasal spray to help relieve depression should be subsidised to make ...
Posted by Michael Wonder on 19 May 2022
Major parties committed to major medicines policy reform and reviews – whoever wins on Saturday
19 May 2022 - Medicines Australia has been assured in official communications from the respective Campaign Headquarters that both the ...
Posted by Michael Wonder on 19 May 2022
BMS’ Sprycel reimbursement criteria to be broadened for paediatric Philadelphia chromosome positive ALL
19 May 2022 - The state health insurance review agency said it would broaden the reimbursement criteria for Sprycel (dasatinib), ...
Posted by Michael Wonder on 19 May 2022
Budget 2022: critically ill patients 'bitterly disappointed' by PHARMAC funding
19 May 2022 - Critically ill patients say they're "bitterly disappointed" by today's PHARMAC Budget announcement and were left looking ...
Posted by Michael Wonder on 19 May 2022
G-BA certifies active ingredients against breast and oesophageal cancer as having a high additional benefit
19 May 2022 - The Federal Joint Committee (G-BA) has rated the patient-relevant additional benefit of two active ingredients for cancer ...
Posted by Michael Wonder on 19 May 2022
SIGA receives approval from the FDA for intravenous formulation of Tpoxx (tecovirimat)
19 May 2022 - FDA approval provides an important option for those unable to take oral formulation of Tpoxx. ...
Posted by Michael Wonder on 19 May 2022
EMA accepts filing of marketing authorisation application for Valneva’s inactivated COVID-19 vaccine candidate
19 May 2022 - 2022 – Valneva today confirmed that the EMA has accepted the filing of a marketing authorisation ...
Posted by Michael Wonder on 19 May 2022
Multiple funding proposals being considered by PHARMAC
19 May 2022 - PHARMAC has issued three consultations today on proposals to fund medicines for conditions including cancer, multiple sclerosis, ...
Posted by Michael Wonder on 19 May 2022
COVID-19 vaccine weekly safety report (19 May 2022)
19 May 2022 - To 15 May 2022, the TGA has received 555 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 May 2022
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread
17 May 2022 - A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the ...
Posted by Michael Wonder on 19 May 2022
PHARMAC will use biggest budget increase ever to fund more medicines for more New Zealanders
19 May 2022 - PHARMAC welcomes the $191 million increase to its pharmaceutical budget over the next two years. ...
Posted by Michael Wonder on 18 May 2022
CMS unveils more user friendly Medicare website
18 May 2022 - New Medicare.gov will incorporate public feedback and make it easier to compare, choose, and understand Medicare ...
Posted by Michael Wonder on 18 May 2022
Alnylam announces Health Canada authorisation of Oxlumo (lumasiran), the first and only treatment for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients
18 May 2022 - Authorization based on two pivotal Phase 3 trials, ILLUMINATE-A and ILLUMINATE-B; showing significant reduction in urinary ...